Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from 10x Genomics

3 Genomic Research Companies Pioneering Personalized Medicine

With vast potential, contribution to rare disease discovery and management, and adoption of AI, the genomic research market is thriving. Hence, fundamentally solid genomic research stocks Agilent Technologies (A), Illumina (ILMN), and 10x Genomics (TXG) could be ideal buys. Read more.

StockNews.com

10x Genomics Crashes After 'Disruptive' Reorg Upsets Third-Quarter Sales

10x Genomics stock crashed Thursday after the medtech reported preliminary third-quarter sales that widely missed Street expectations.

Investors Business Daily

1 Cathie Wood Stock With 55% Upside Potential

This Ark Invest biotech stock pick, with 55% potential upside, garnered a vote of confidence from Jefferies last week.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Highflier 10x Genomics Sacrifices Breakout As Macro Headwinds Squeeze China

Life science company 10x Genomics beat second-quarter sales forecasts, but TXG stock tumbled Friday on macro challenges and steeper losses.

Investors Business Daily

Dow Jones Falls As McCarthy Urges Biden To Beat This Addiction; DraftKings Pops On Upgrade As Apple Dips

The Dow Jones dipped as House Speaker Kevin McCarthy issued a challenge to President Joe Biden. DraftKings soared. Apple stock dipped after a downgrade.

Investors Business Daily

Will 10x Genomics Disappoint Investors Again?

The lab hardware provider has been whacked by a strong U.S. dollar, which only grew stronger during the third quarter.

The Street

Pacific Biosciences' Tools Expansion Doesn't Guarantee Success

Recent announcements are likely better news for 10x Genomics and Twist Bioscience than the DNA sequencing pioneer.

The Street

Read news from The Economist, FT, and more,
with one subscription

A Strong Dollar Could Whack These Biotech Stocks

Twist Bioscience, 10x Genomics, and others with large international exposure could be squeezed by global currency selloffs.

The Street

Meme-Stock Mania Is Leaving These Genomics Stocks

A handful of biotech stocks were catapulted higher by short squeezes. Whether they will recover their losses is an open question.

The Street

PacBio (Still) Lags on This Crucial Metric

The genomics company PacBio isn't making much progress in the most important source of revenue.

The Street

10x Genomics Stock Rebound Depends on Growth

The formerly high-flying growth stock is stalling against macroeconomic headwinds. How quickly can the business get back on track?

The Street

From Illumina to Twist Bioscience, a Strong Dollar Is Bad News

Wall Street hasn't fully digested what currency devaluation really means for biotech stocks.

The Street

Popular Biotech Growth Stock Is Bitten by a Strong Dollar

10x Genomics expects to report that second-quarter revenue declined from a year earlier.

The Street

Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

10x Genomics Crashes On Sales Disappointment, Extending A Yearlong sell-off

TXG stock crashed Friday after genetic technology outlet 10x Genomics preannounced lackluster second-quarter sales.

Benzinga

10x Genomics's Return On Capital Employed Overview

10x Genomics (NASDAQ:TXG) brought in sales totaling $114.50 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 129.89%, resulting in a loss of $42.41 million.

The Street

A Beaten-Down Biotech Stock That's Finally Attractive

This lab-hardware business is growing, cashed up, and close to profitability.

Benzinga

10x Genomics: Q1 Earnings Insights

10x Genomics (NASDAQ:TXG) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

4 Analysts Have This to Say About 10x Genomics

Analysts have provided the following ratings for 10x Genomics (NASDAQ:TXG) within the last quarter:

Benzinga

10x Genomics Posts Topline Growth Of 8%, Reaffirms FY22 Guidance

10x Genomics (NASDAQ: TXG) reported

Benzinga

10x Genomics: Q1 Earnings Insights

10x Genomics (NASDAQ:TXG) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings 10x Genomics missed estimated earnings by 22.58%, reporting an EPS of $-0.38 versus an estimate of $-0.31.

StockNews.com

Teladoc vs. 10x Genomics: Which Beaten-Down Health Information Services Stock Is a Better Buy?

Today I'll analyze and compare Teladoc (TDOC) and 10x Genomics (TXG) to determine which stock is a better buy.

Benzinga

10x Genomics Shares Plunge On Disappointing Q4 Earnings, FY22 Outlook

10x Genomics Inc (NASDAQ: TXG)

Benzinga

Recap: 10x Genomics Q4 Earnings

10x Genomics (NASDAQ:TXG) reported its Q4 earnings results on Wednesday, February 16, 2022 at 04:05 PM. Here's what investors need to know about the announcement.

Benzinga

A Preview Of 10x Genomics's Earnings

10x Genomics (NASDAQ:TXG) is set to give its latest quarterly earnings report on Wednesday, 2022-02-16. Here's what investors need to know before the announcement. Analysts estimate that 10x Genomics will report an earnings per share (EPS) of $-0.09.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.